Why Canopy Growth (TSX:WEED) Stock Soared 22% Higher This Week

Canopy Growth stock is making a comeback as its valuation improves and a Biden win increases optimism for U.S. cannabis legalization.

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) was the first North American cannabis company to be publicly traded. It has been through many ups and downs as Canada worked hard in the early days of legalization. Management has been shuffled, strategic investors have entered the picture, and a bubble was burst.

This week, we saw renewed optimism and hope coming from this once astronomically valued cannabis stock. Biden is now president-elect, easing the path to federal legalization of cannabis in the United States. And Canopy Growth’s fiscal 2021 second-quarter results and outlook are strong.

In response to all of this, Canopy Growth stock rallied 22% in the last five days, so things are looking up. Read on for more detail.

Canopy Growth posts solid revenue growth in Q2

As the cannabis company that benefits from first mover advantage, Canopy Growth is still the go-to stock for investors. The company has a sizable cash balance of almost $2 billion and is finally forecasting positive adjusted EBITDA.

Adjusted second quarter revenue increased 23%. It’s not the kind of revenue growth that we saw when Canopy Growth first became public, as Canopy Growth stock valuation doesn’t reflect that type of unrealistic growth anyway. Today, the stock’s valuation reflects a more realistic growth path.

As well, it’s better quality revenue growth accompanied by significant cost reductions and market share gains. This, in turn, has led management to forecast that the company will achieve positive adjusted EBITDA at some point in fiscal 2021.

This is all pretty huge. Canopy Growth is making market share gains, opening new stores, and cutting expenses drastically. This is finally a business to consider investing in.

Biden win is positive for federal marijuana reform in the U.S.

Now that Biden has won the U.S. presidential race, that country may further destigmatize and normalize the use of cannabis. Federal legislation may accompany this now that the democrats have gained the presidency.

Biden doesn’t believe that anyone should be in jail for marijuana use. The decriminalization of marijuana is well under way in the U.S. Eleven states already allow for the consumption and/or retail sale of marijuana. According to Gallup polls, 66% of polled Americans favour national legalization of marijuana.

Canopy Growth stock’s valuation reset

In the height of the marijuana bubble, Canopy Growth stock was trading at bubble valuations. Its price to sales multiple was well over 100 times back in 2018. As I pointed out back then, this was not sustainable. And the stock went on the plummet 74.5% from its highs in 2018 to lows of $18.78 in October of 2019.

That’s a far cry from bubble levels. Canopy Growth stock’s price to sales multiple went from a price to sales multiple of over 100 times to today’s multiple of 25 times. I would much rather own the stock today when expectations are more reasonable. The stock is not priced for perfection anymore. The company therefore has a little more wiggle room.

Motley Fool: the bottom line

Canopy Growth stock has rallied in the last week as the market is rewarding the company’s progress. Also, the macro environment is looking better as Biden has won the presidential race. Federal legalization in the U.S. is now looking more plausible.

This cannabis stock has big upside today with much less downside than we have grown accustomed to with this sector. In my view, the risk/reward is very favourable today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »